Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Blends & Stacks/Retatrutide + Cagrilintide
Metabolic Blend
Reta/Cagri · "RetaCagri" · triple agonist + amylin analogue
Hunger suppressed from one end, fullness accelerated from the other. A direct extrapolation of the CagriSema design onto a molecule that has never been paired with an amylin analogue in any trial.
The logic is borrowed, and the source is good. Cagrilintide plus semaglutide — the CagriSema programme — established at phase 1b and then at phase 3 that adding a long-acting amylin analogue to a GLP-1 agonist produces greater weight reduction than the incretin alone, with tolerable safety.[1][2] The mechanism is complementary: incretins reduce hunger, amylin accelerates fullness, and the two act on anatomically separate circuits.
The community stack applies that finding to retatrutide instead of semaglutide. The stated goal is usually not maximal weight loss but dose-sparing: if cagrilintide supplies part of the appetite control, retatrutide can stay at a lower dose, and retatrutide's adverse effects are dose-ordered.
The substitution is not free. Retatrutide is not semaglutide with extra receptors — it carries a glucagon arm that raises energy expenditure, raises heart rate, and pushes hepatic glucose output. Whether an amylin analogue behaves the same way alongside that as it does alongside a pure GLP-1 agonist has never been examined. No trial has ever combined these two molecules.
Both components slow gastric emptying independently. Stacking them stacks that effect — including the anaesthesia aspiration risk that has become a recognised concern across the incretin class. Anyone with a procedure scheduled should treat this as directly relevant.
Retatrutide — the intake side. GLP-1 agonism suppresses appetite and the reward salience of food; GIP agonism adds insulinotropic effect and blunts the nausea signalling of pure GLP-1 agonism; glucagon-receptor agonism raises resting energy expenditure and drives hepatic fatty-acid oxidation. Together: eat less, burn more.
Cagrilintide — the meal-termination side. Amylin receptor agonism in the area postrema and nucleus tractus solitarius signals that a meal is complete. Calcitonin receptor agonism contributes additional and reportedly more durable weight effect. Pre-clinical work also links amylin agonism to restored leptin sensitivity.
Why they add rather than overlap. Hunger and satiation are separable processes with separable circuitry. A user on retatrutide alone reports not thinking about food; a user on cagrilintide alone reports eating a small amount and stopping. Combining them addresses both.
The dose-sparing argument. Retatrutide's adverse events are dose-ordered — GI burden, heart rate rise, glycaemic pressure all scale with dose. If cagrilintide contributes appetite control at a low dose with a modest GI cost of its own, total adverse-effect burden should fall for equivalent weight loss. Coherent reasoning; no trial has tested it for this pair.
A blend is not a compound. It is several compounds sharing a vial, and each one carries its own evidence base, dose-response curve and risk profile. Study them individually before studying them together.
| Component | Share of blend | Role in the blend | Monograph link |
|---|---|---|---|
| Retatrutide LY3437943 |
Separate: titrated - Pre-mix: 12.5 mg of 15 (83%) | Triple agonism at GLP-1, GIP and glucagon receptors — appetite and food-noise suppression, delayed gastric emptying, plus increased energy expenditure and hepatic fat oxidation from the glucagon arm. | Monograph |
| Cagrilintide AM833 |
Separate: fixed low - Pre-mix: 2.5 mg of 15 (17%) | Amylin and calcitonin receptor agonism — hindbrain meal-termination signalling and slowed gastric emptying, acting on satiety circuits the incretins do not reach. | Monograph |
This is usually a co-administration of two vials, but a pre-mixed presentation does circulate — commonly a 15 mg vial split 12.5 mg retatrutide to 2.5 mg cagrilintide, a fixed 5:1 ratio.
That ratio does not match the protocols. The widely circulated pairing is 1 mg retatrutide with 0.5 mg cagrilintide — a 2:1 ratio. Drawing enough pre-mix to deliver 1 mg of retatrutide yields only 200 mcg of cagrilintide, well under half the intended amount. Reaching 0.5 mg of cagrilintide instead means taking 2.5 mg of retatrutide, more than double the intended dose.
A fixed-ratio vial cannot do what every circulating protocol asks for: hold cagrilintide constant while titrating retatrutide. If that is the plan, two separate vials are the only way to run it — which is also why mixing two reconstituted peptides in one syringe keeps coming up, and that introduces pH, compatibility and stability questions nobody in this setting is testing for.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Phase 1b established tolerability and greater weight reduction for cagrilintide co-administered with semaglutide 2.4 mg than for semaglutide alone; the phase 3 programme confirmed substantially greater weight reduction than semaglutide monotherapy.
Phase 2 trial in adults with obesity, 12 mg arm, with the weight curve not yet plateaued at trial end.
Phase 2 dose-finding trial, outperforming liraglutide 3.0 mg.
Zero human, animal or in vitro data exists for this specific pair.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The principal rationale for the stack. Follows from additivity plus dose-ordered adverse events. Never studied as a dose-reduction strategy for retatrutide.
Direct extrapolation from CagriSema. The assumption is that retatrutide behaves like semaglutide as an amylin partner, which is not established.
From the amylin leptin-re-sensitisation literature. Speculative.
A frequently repeated claim about amylin agonism. Body-composition sub-studies in the combination programmes are the place to test it, and it should be treated as open.
The practical version of the dose-sparing argument. Plausible; both components have GI effects, so "better" is relative, not absolute.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The dominant report and the reason the stack exists in the community. Uncontrolled but consistent.
Users describe retatrutide as removing food thoughts and cagrilintide as making meals end early — a distinction that maps precisely onto the two mechanisms.
Less late-week appetite return with both long-half-life compounds on board.
Adding even 0.5 mg cagrilintide to an established incretin is frequently reported as producing disproportionate nausea and constipation. Consistent with additive mechanism.
Both being once-weekly makes co-administration convenient. Mixing in one syringe is common and unvalidated.
A recurring practical complaint: intake falls so far that protein becomes hard to hit, undercutting the lean-mass rationale that usually accompanies the stack.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
The CagriSema data shows higher total GI adverse-event rates for the combination than either component alone — better tolerated than an equivalent incretin escalation, which is not the same as well tolerated.
Documented in the phase 2 programme, attributed to glucagon-receptor-mediated energy expenditure. The dose-sparing rationale, if it works, reduces this.
Pancreatitis, gallbladder disease, acute kidney injury from dehydration, retinopathy complications with rapid glycaemic change, and the rodent-derived medullary thyroid carcinoma contraindication.
Pramlintide, the approved amylin analogue, carries a boxed warning for severe insulin-induced hypoglycaemia and mandates insulin dose reduction on initiation.
A consistent finding in body-composition sub-studies of rapid pharmacological weight loss.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Two independent gastric-emptying delays. Directly relevant to any planned procedure requiring sedation.
The specific gap. CagriSema paired amylin with a pure GLP-1 agonist; retatrutide adds a glucagon arm that raises hepatic glucose output. No data describes how these interact.
Rapid weight loss is an established gallstone risk factor, and this stack is designed to accelerate loss.
Compounded by the reported difficulty maintaining protein intake at this degree of appetite suppression.
Grey-market retatrutide and cagrilintide both have documented product-quality variability, and cagrilintide is chemically demanding to synthesise.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The most prominent complaint in long-run community logs for this stack, more than nausea.
Widely reported and often the trigger for dose reduction.
Reported at 3–5 months and attributable to rapid weight loss and inadequate intake as much as to the compounds.
Consistent with the documented heart-rate effect.
Appearing periodically in community reports, matching the known rapid-loss association.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly, reached by co-escalation. The only studied amylin + incretin dosing.
Every figure below is community-derived.
| Studied combination | Amylin | Incretin | Result |
|---|---|---|---|
| CagriSema (phase 1b) | Cagrilintide 2.4 mg | Semaglutide 2.4 mg | Greater loss than semaglutide alone |
| CagriSema (phase 3) | Cagrilintide 2.4 mg | Semaglutide 2.4 mg | Substantially greater than monotherapy |
| Reta + Cagri | — | — | Never studied |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Keeps one variable constant so any change is attributable. This is what circulating protocols do, and it is the more interpretable design.
If cagrilintide carries a lower adverse-effect cost per unit of appetite control, raising it is the lower-burden escalation. Untested claim.
Both have half-lives near a week; same-day dosing keeps the exposure profiles aligned. Convenience reasoning.
Both components have dose-ordered GI effects. Once appetite control is adequate, further escalation of either buys side effects rather than benefit.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The pairing specified in the Gold Standard protocol. Retatrutide raised by 0.5 mg every 4 weeks only if weight loss has plateaued for ≥2 weeks (≥4 weeks for women) and only if there are zero side effects; cagrilintide held fixed.
A higher circulating tier for users who have escalated over months.
Rather than starting both together, adding cagrilintide when retatrutide alone stalls.
Low doses of both continued to defend against regain. Longest cumulative exposure, no data.
| Community tier | Retatrutide | Cagrilintide | Frequency |
|---|---|---|---|
| Gold Standard Protocol | 1 mg (titrated) | 0.5 mg (fixed) | Once weekly |
| Entry | 0.5 – 1 mg | 0.25 – 0.5 mg | Once weekly |
| Standard | 1 – 2 mg | 0.5 – 1 mg | Once weekly |
| Escalated | 2 – 4 mg | 1 – 2.4 mg | Once weekly |
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The most common third addition. GH is nitrogen-sparing in principle; it also worsens glucose handling, which stacks with the glucagon arm of retatrutide in an unfavourable direction that community protocols rarely acknowledge.
The stated reason KLOW or GLOW appears alongside aggressive fat loss.
AMPK activation alongside incretin-driven intake reduction. Two glucose-lowering pressures stacked, and AMPK suppresses mTOR — working against any concurrent lean-mass goal.
The only "synergy" in this whole stack with a solid independent evidence base — and the one most compromised by the degree of appetite suppression the stack produces.
Amylin analogues plus incretins plus insulin therapy is a hypoglycaemia scenario with a boxed-warning precedent in the amylin class.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
This pairing anchors position 1 of the Gold Standard protocol and the Q1 phase of the 15-Compound Matrix.
Routine community practice for the constipation and fatigue. Low-risk supportive measures.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Registered phase 3 protocols for the fixed-dose combination in obesity and type 2 diabetes, with defined co-escalation schedules, monitoring and stopping rules.
Registered phase 3 protocols for retatrutide monotherapy across obesity, T2D, cardiovascular risk and knee osteoarthritis.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Holding cagrilintide fixed while moving retatrutide is the only way to attribute a change to a cause.
Resting heart rate, blood pressure, HbA1c and fasting glucose, lipase, liver panel, lipids, and body composition. This is what the trials measured and what unmonitored use omits.
Given documented lean-mass loss and the practical difficulty of eating enough on this stack, this is the part that most needs deliberate planning.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
1 mg retatrutide weekly with 0.5 mg cagrilintide weekly. Increase retatrutide by 0.5 mg every 4 weeks only on a genuine ≥2-week plateau (≥4 weeks for women) and only with zero side effects.
Opens the year-long phased matrix, before regenerative, anabolic and neuro-cognitive compounds are layered in, on the stated principle of never introducing multiple modalities at once.
This is a community-assembled combination of two investigational compounds, and its conditions are the conditions of its components. What is specific to the blend is the reasoning behind combining them, which is worth examining because there is a trialled version of the same idea and it did not behave as expected.
Neither component is approved anywhere, and this combination has never been studied in anything. Retatrutide has completed phase 3 — the TRIUMPH programme — with a licence application planned for early 2027; cagrilintide has no standalone programme at all. Combining two investigational compounds does not average their uncertainty — it compounds it, and it removes any possibility of attributing an effect or an adverse event to either.
Pathophysiology
Obesity is physiologically defended, and combining mechanisms is the current strategy for overcoming compensatory responses.
Mechanistic rationale
The stacking logic — a multi-agonist incretin plus an amylin analogue — is the same logic behind CagriSema, which is the one amylin-plus-incretin combination actually tested. REDEFINE-1 landed below market expectation, which suggests combining these mechanisms is not simply additive. A home-assembled version of an idea whose trialled form underperformed expectation deserves less confidence than it usually receives, not more.
Community reports
Among the most-discussed grey-market stacks. Retatrutide alone produced the largest phase 2 weight reductions in the class, which is most of the appeal.
Components carrying the argument: Triple agonist + amylin analogue
Pathophysiology
Insulin resistance with beta-cell failure.
Mechanistic rationale
TRIUMPH-2 reported HbA1c reductions of up to 1.6 percentage points alongside 20.8% weight loss over 80 weeks in 1,152 adults with type 2 diabetes — so the glucagon concern, that hepatic glucose output would undermine the other two arms, did not materialise at phase 3 scale. It remains unapproved, and the programme did not include a cardiovascular outcome trial, in a condition where two approved alternatives have one.
Community reports
Used by people with diagnosed diabetes, frequently alongside insulin or a sulphonylurea, without dose reduction of either.
Components carrying the argument: GLP-1 + GIP + glucagon, plus amylin
Pathophysiology
Amylin analogues lower glucose independently of insulin; both components slow gastric emptying.
Mechanistic rationale
The pramlintide boxed warning for severe insulin-induced hypoglycaemia is the class precedent for the amylin half, and it applies here. Separately, two compounds delaying gastric emptying at once produces additive GI burden and additive effects on oral drug absorption — levothyroxine especially.
Community reports
Disproportionate nausea on adding cagrilintide to an established incretin is consistently reported.
Components carrying the argument: Both components
Pathophysiology
Incretin agonists raise heart rate modestly; the effect was dose-dependent in retatrutide phase 2.
Mechanistic rationale
No cardiovascular outcome trial has reported for either component. Semaglutide, liraglutide, dulaglutide and tirzepatide all have that data; these do not. The compounds with the largest demonstrated weight effects are the ones with the least outcome evidence, and that is the trade being made. TRIUMPH-3 enrolled a cardiovascular-disease population but was not powered for cardiovascular endpoints, and its two MACE composites point in opposite directions.
Community reports
Resting heart rate is rarely tracked, and it is one of the easier things to measure.
Components carrying the argument: Retatrutide, dose-dependent
| Question | Position |
|---|---|
| Studied as a combination? | Never |
| Component approval | Neither — retatrutide phase 3 complete, BLA planned Q1 2027 |
| Trialled analogue | CagriSema — which underperformed expectation |
| Ratio | Vendor-dependent; verify your vial |
| On insulin? | See the pramlintide boxed warning |
| Cardiovascular outcome data | None for either component |
For obesity: the approved incretins have both the largest demonstrated effects and cardiovascular outcome data. Bariatric surgery produces the largest and most durable results of any intervention. An energy deficit that can be maintained, resistance training to protect lean mass, protein, sleep, and treatment of undiagnosed sleep apnoea.
For type 2 diabetes: metformin first, then SGLT2 inhibitors and GLP-1 agonists chosen on the outcome data, with any background insulin or sulphonylurea reduced whenever another glucose-lowering agent is added.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Two separate lyophilised vials in most cases — retatrutide commonly 5–30 mg, cagrilintide commonly 5–10 mg. Both reconstituted with bacteriostatic water. At weekly microdoses a single vial of either can last two to three months reconstituted, which is well beyond any characterised in-use stability window for these molecules.
Lyophilised: −20 °C long-term, protected from light. Reconstituted: 2–8 °C. Cagrilintide is an amylin-family peptide and therefore aggregation-prone — haze or visible fibril means discard.
Retatrutide 10-30 mg; cagrilintide 5-10 mg. Pre-mixed combination vials circulate at 15 mg total (12.5 mg retatrutide / 2.5 mg cagrilintide).
The long in-use period is the specific problem with this pairing. A 10 mg retatrutide vial at 1 mg weekly is ten weeks in the refrigerator.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Both components are investigational; neither is approved anywhere as a standalone product. Retatrutide is in phase 3; cagrilintide has progressed through phase 3 only as part of a fixed-dose combination with semaglutide.
Regulatory progress for CagriSema confers nothing on grey-market retatrutide + cagrilintide, which is a different combination of different material from a different source.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: component phase 3 status via the retatrutide audit. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Peptide hormones and metabolic modulators are addressed under the WADA Prohibited List. Tested athletes should treat unapproved investigational metabolic agents as prohibited until specifically verified otherwise.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
